Trial Profile
Phase 1/2 Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Jan 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Feb 2020 Status changed from active, no longer recruiting to completed.
- 07 Nov 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 07 Nov 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.